Order Article Reprints

Seijas-Amigo J, Mauriz-Montero MJ, Suarez-Artime P, Gayoso-Rey M, Reyes-Santías F, Estany-Gestal A, Casas-Martínez A, González-Freire L, Rodriguez-Vazquez A, Pérez-Rodriguez N, et al. Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study. Diseases. 2024; 12(10):244. https://doi.org/10.3390/diseases12100244

Seijas-Amigo, José, Maria José Mauriz-Montero, Pedro Suarez-Artime, Mónica Gayoso-Rey, Francisco Reyes-Santías, Ana Estany-Gestal, Antonia Casas-Martínez, Lara González-Freire, Ana Rodriguez-Vazquez, Natalia Pérez-Rodriguez, and et al. 2024. "Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study" Diseases 12, no. 10: 244. https://doi.org/10.3390/diseases12100244

Seijas-Amigo, J., Mauriz-Montero, M. J., Suarez-Artime, P., Gayoso-Rey, M., Reyes-Santías, F., Estany-Gestal, A., Casas-Martínez, A., González-Freire, L., Rodriguez-Vazquez, A., Pérez-Rodriguez, N., Villaverde-Piñeiro, L., Castro-Rubinos, C., Espino-Paisán, E., Cordova-Arevalo, O., Rodriguez-Penas, D., Cardeso-Paredes, B., Ribeiro-Ferreiro, M., Rodríguez-Mañero, M., Cordero, A., ... MEMOGAL Investigators. (2024). Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study. Diseases, 12(10), 244. https://doi.org/10.3390/diseases12100244